Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

[1]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[2]  P. Katsikis,et al.  Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion1 , 2009, The Journal of Immunology.

[3]  Scott N. Mueller,et al.  High antigen levels are the cause of T cell exhaustion during chronic viral infection , 2009, Proceedings of the National Academy of Sciences.

[4]  T. Mak,et al.  Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.

[5]  D. Getnet,et al.  Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1 , 2009, The Journal of Immunology.

[6]  T. Jacks,et al.  Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. , 2008, Cancer research.

[7]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[8]  Jianzhu Chen,et al.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice , 2008, Proceedings of the National Academy of Sciences.

[9]  O. Finn.  Immunological Weapons Acquired Early in Life Win Battles with Cancer Late in Life , 2008, The Journal of Immunology.

[10]  M. Schwaiger,et al.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.

[11]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[12]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[13]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[14]  Achim A. Jungbluth,et al.  Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes , 2008, Science.

[15]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[16]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[17]  T. Mak,et al.  TNF-α is critical for antitumor but not antiviral T cell immunity in mice , 2007 .

[18]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[19]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[20]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[21]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[22]  T. Mak,et al.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. , 2007, The Journal of clinical investigation.

[23]  Ekaterina S Jordanova,et al.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.

[24]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[25]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[26]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[27]  I. Huijbers,et al.  An inducible mouse model of melanoma expressing a defined tumor antigen. , 2006, Cancer research.

[28]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[29]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[30]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[31]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[32]  E. Jaffee,et al.  Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.

[33]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[34]  William L Redmond,et al.  Peripheral tolerance of CD8 T lymphocytes. , 2005, Immunity.

[35]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[36]  H. Levitsky,et al.  Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression , 2004, The Journal of experimental medicine.

[37]  J. Biggs,et al.  A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL1 , 2004, The Journal of Immunology.

[38]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[39]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[40]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[41]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[42]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[43]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[44]  D. Speiser,et al.  Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance , 2002, The Journal of experimental medicine.

[45]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[46]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[47]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[48]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[49]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[50]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[51]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[52]  Kathleen M. Smith,et al.  Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. , 1997, International immunology.

[53]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[54]  H. Koeppen,et al.  Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. , 1990, Cancer research.

[55]  C. Uyttenhove,et al.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.

[56]  O RAJKA,et al.  [TUMOR IMMUNOLOGY]. , 1963, Orvosi hetilap.